Haidong Dong
@hd_DongMDPhD
Followers
309
Following
499
Media
2
Statuses
78
#TumorImmunology/immunotherapy. To identify and produce resilient cytotoxic T cells for cancer immunotherapy.
Joined February 2011
đšïž Just published in @NatureBiotech: Our CellWhisperer AI enables chat-based analysis of single-cell sequencing data. You can talk to your cells & figure out the biology without writing any computer code. Paper link and annotated walkthrough in the thread below (1/11)
12
183
683
1
33
98
New #JITC article: Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion https://t.co/OdQDEb1uND
@flscientist @hd_DongMDPhD
0
5
14
You donât need to cut out a tumor to find tumor-killing T cells. Rosenbergâs group mapped circulating neoantigen-specific CD8âș T cells that can be sorted right from blood: CD45ROâș HLA-DR^hi CD39âș CD103âș. Yossef et al., Cancer Cell
cell.com
Yossef et al. report that antitumor T cells in the blood of metastatic cancer patients exhibit a distinct transcriptional profile. They further show that this gene signature can be leveraged to...
3
35
155
Our discovery of targeting myeloid cellsâ PD-L1 in cancer therapy is highlighted in this news release:
newsnetwork.mayoclinic.org
Mayo Clinic researchers discovered targeting myeloid cells can boost cancer immunotherapy by enhancing T-cell activity and overcoming resistance. A clinical trial is planned.
0
1
10
Congratulations to our team and lead author Michelle for this publication today!! A new generation of PD-L1 antibody (H1A) leverages myeloid cells to promote T cell immunity against cancer.
jitc.bmj.com
Background Immune checkpoint therapies targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been met with limited clinical responses in the treatment of...
1
2
9
Our review is officially published: A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity
aacrjournals.org
Abstract. The effectiveness of T cellâbased immunotherapy depends on durable T-cell responses that can efficiently eliminate tumor cells. NKG7 was discovered three decades ago as a protein associated...
0
0
5
Our new humanized both PD-1 and PD-L1 mice are now available at the Jax lab with an RRID. Thank you all for your interest in use of this mouse model to shorten preclinical and clinical space for targeting this pathway. The link for strain details:
0
4
26
Speaker Spotlight for Mayo Clinic RNA Discoveries and Therapeutics Conference on our FL campus on May 30-31, 2025, livestream option. Excited to have @hd_DongMDPhD from @MayoClinic as a presenter. Donât forget to register and submit abstracts. https://t.co/Pg4o2fjSN8
@DoctorQMd
1
2
11
T cell longevity, a new role of NKG7 there.
newsnetwork.mayoclinic.org
Mayo Clinic researchers have discovered a new role that a specific protein plays in regulating cell resistance and fighting tumors in certain types of cancer.
0
5
24
What is cancer immunotherapy ? A brief introduction of that at Mayo Clinic.
cancerblog.mayoclinic.org
Drs. Haidong Dong and Svetomir Markovic, Mayo Clinic immunologists, discuss how immunotherapy works, its benefits and risks, and why theyâre excited about its future.
0
0
4
@hd_DongMDPhD Nice paper! Wanted to share a poster from ASH 2023 Corvus Pharmaceutical $CRVS oral ITK inhibitor soquelitinib induces #NKG7 which reduces mTORC1 and promotes CD8+ Tcell memory, reduces T-cell exhaustion genes (PD-1, LAG-3, TIM-3). soquelitinib in Ph3 trial for PTCL, starting
0
2
5
A key feature of resilient T cells is revealed: Lysosomal NKG7 restrains mTORC1 activity to promote CD8+ T cell durability and tumor control. https://t.co/m9PtpiW2qC Congratulations!!! June, Dan, Henrique and all authors!!
1
6
21
Mayoâs Cancer CARE Beyond Walls program is transforming the cancer treatment experience for patients to offer more convenience and a better quality of life. Dr. Roxana Dronca shares more: https://t.co/DKvRk4CikS
0
3
19
Happy to share my thesis work as preprint in @biorxiv_immuno ! We found an interesting role of PD-1 in regulating the effector cytotoxic and exhaustion potential of thymic mature CD8+ T cells, which impacts the maintenance of peripheral tumor immunity.
biorxiv.org
Durable T cell immunity against cancer depends on the continual replenishment of effector CD8+ T cells. Thymic output has been correlated with favorable prognosis in cancer patients across a range of...
4
13
58
PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity https://t.co/3Yvm1ntnX6
#biorxiv_immuno
1
2
10
PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity https://t.co/k9pnMwP6Be
@hd_DongMDPhD @Zhiming_Mao
0
13
81
The discovery of T cell receptor (TCR) was a major breakthrough and paved the way for significant advances in the fields of T cell biology and immunotherapy.
A fantastic day celebrating the 40th anniversary of the discovery of the TCR. Check out this T cell speaker photo which includes co-discoverers Tak Mak and Mark Davis. Thanks @UofT, @uoftmedicine, @ImmunologyUofT, @thePMCF for your support.
0
2
13